February 27, 2015
Researchers presented results from an evaluation of characteristics and demographics of adolescents with chronic idiopathic urticaria and chronic spontaneous urticaria in placebo-controlled omalizumab trials at the American Academy of Allergy, Asthma and Immunology Annual Meeting in Houston.
Stanley Goldstein, MD, FAAAAI, and colleagues conducted a post-hoc descriptive analysis of pooled baseline data from three trials examining omalizumab use in 975 patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remained symptomatic despite treatment with H1 antihistamines. In one study, H2-antihistamines and/or leukotriene receptor antagonists (LTRA) were used. The researchers summarized the patient demographics and disease characteristics for patients overall and for adolescent patients ages 12 years and older but younger than 18.